Challenges to perform an efficiently gene therapy adopting non-viral vectors: Melanoma landscape

Author(s)

Viegas, Juliana Santos Rosa ; Bentley, Maria Vitoria Lopes Badra ; Vicentini, Fabiana Testa Moura de Carvalho

• Document type: Journal article
• Source: JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY; v. 78, p. 18-pg., 2022-11-14.

Abstract

The gene therapy is an alternative approach to melanoma treatments due to several drug resistance that this type of cancer developed and to perform an efficiently in vivo gene therapy the use of vectors is generally required. The non-viral vectors can guarantee the biological effect of DNA or RNA, increasing their stability and uptake, also, presenting lesser adverse effects and immunogenicity than viral-based ones, however, to perform an in vivo gene therapy there are plenty of challenges to be faced. This review, considering the fact that there is no ideal non-viral vector for melanoma gene therapy, but rather, there are several possibilities that bring us relevant and illustrative contributions on the magnitude of this subject, points out the main challenges to perform gene therapy from non-viral vectors for the melanoma skin cancer, focusing on the most studied strategies to overcome them. In this way it was considered as challenges: the administration route and the vector choice; aspects in the non-viral vectors' preparation process; effectiveness and safety, and pre-clinical and clinical aspects. (AU)

• FAPESP's process: 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach
• Grantee: Maria Vitória Lopes Badra Bentley
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 19/04448-2 - Development of a nanostructured lipid carrier containing pool of siRNAs associated with the antitumor agent as a multifunctional therapeutic approach for skin Cancer
• Grantee: Juliana dos Santos Rosa
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 19/08891-8 - The use of ferritin nanoparticles as a basis for the development of antitumor vaccine delivery systems
• Grantee: Fabiana Testa Moura de Carvalho Vicentini
• Support Opportunities: Regular Research Grants